You know the drill on bond yields, there is little to none. In this environment, investors have crowded into equities that have better yields than their company’s debt, like utilities, pharma and telcos. From time …
Continue readingPFE
In late 2015 we initiated a long term long position in Pfizer (PFE) with the idea that we could own something that was unfairly punished on the merger announcement with Ireland based Allergan. We wanted …
Continue readingFor week’s now my co-panelist on CNBC’s Options Action, Carter Worth of Cornerstone Macro Research has been making the bullish case for the Biotech stocks, specifically looking at the IBB, the iShares Nasdaq Biotech etf. …
Continue readingBack in late November, the day the long rumored buyout/merger agreement between Pfizer (PFE) and Ireland based maker of Botox, Allergen (AGN) was announced, I said the weakness in PFE leading up to the deal made the stock …
Continue readingIn late November we bought Pfizer (PFE) stock and sold a January upside call (creating an over-write) after the stock sold off on the news of the long rumored merger with Allergen. Here was the …
Continue readingOn November 23rd Pfizer (PFE) officially announced their rumored takeover/ inversion of Ireland based Allergan (AGN). Both stocks sold of the day of the announcement and we felt the initial move was likely wrong and …
Continue readingHere is a quick recap of trades that we initiated, closed, or debated in the week that was Nov 23rd to Nov 27th:
Continue readingThis morning Pfizer (PFE) announced the long rumored buyout/merger agreement with Ireland based maker of Botox, Allergen (AGN), valuing it at $160 billion. While cost cutting and empire building are at the heart of the …
Continue readingI didn’t expect it to happen this quickly. But the fact that negative currency headwinds for U.S. multinationals has already trumped the benefit of lower input costs from the collapse in industrial commodities is quite …
Continue readingOptions market volumes were much higher on Wednesday, even as stock volumes were still relatively light. Many large cap stocks saw large prints, included here: 1. PFE – Trader rolled down a long Sept 32 call …
Continue reading